AbbVie Inc. (ABBV) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
AbbVie Inc. (ABBV) Profile & Business Summary
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Key Information
| Ticker | ABBV |
|---|---|
| Leadership | Robert A. Michael |
| Exchange | NYSE |
| Official Site | https://www.abbvie.com |
Market Trend Overview for ABBV
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
This model looks at how prices behave over time to describe the current market environment. It focuses on whether price is moving steadily, stalling, or losing momentum, and checks both short-term and weekly trends for confirmation. The goal is not to predict exact prices, but to help understand when conditions are supportive, risky, or unclear.
Current Market Context (Short-Term)
As of 2026-02-06 (ET), ABBV is moving sideways. Price at 223.43 is moving between support near 220.23 and resistance near 226.86. There is no clear direction right now. View Support & Resistance from Options
Why the market looks this way?
Prices have moved back and forth over recent sessions without making steady progress. Trend signals have changed frequently, which suggests the market is stuck in a range. In this environment, chasing moves in either direction is less reliable.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-02-06 (ET)
As of 2026-02-06, ABBV is moving sideways with low volatility. Over the longer term, the trend remains bullish.
ABBV last closed at 223.43. The price is about 0.1 ATR below its recent average price (223.97), and the market is currently in a sideways market with low volatility.
Price is moving in a tight range. This often leads to a stronger move once the range breaks, increasing one-sided risk.
Trend score: 40 out of 100. Overall alignment is unclear. The market is currently in a sideways phase with tightening price movement. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear risk level acting as a key boundary right now.
A systematic trend-activation signal was most recently triggered on 2026-02-02, reflecting a technical shift toward positive directional alignment.
[2025-12-31] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
Short Interest & Covering Risk for ABBV
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is at a very high historical level. If price moves against shorts, reactions could be sharp and volatile. (Historical percentile: 90%)
Structure Analysis
ABBV Short positioning looks normal. Current days to cover is 2.9 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves.
Bull Trap Structural Risk
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
In the latest reporting period, short interest continues to increase. Price is consolidating near highs with a weak upward bias, appearing strong on the surface but structurally more fragile. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-01-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.